LLY Stock Too Cheap At $750?
LONDON,ENGLAND - MAY 30: A photo illustration of a Mounjaro pen on May 30 2025 in London, England. ... More Mounjaro is a treatment for weight loss and type 2 diabetes. (Photo by Peter Dazeley via Getty Images)
Question: Why would you pay 81 times earnings for AbbVie stock when you can buy LLY for a similar valuation of 76 times earnings? You wouldn't, especially when you consider three simple facts:
Safe Bet? While Eli Lilly (LLY) might not be a traditional "safe haven" stock, its past performance during market shocks offers some perspective. During the 2022 inflation shock, LLY stock saw a 19% decline, and it fell 23% during the 2020 COVID-19 pandemic market correction.
However, when compared to the broader market, LLY has demonstrated relative resilience. The S&P 500 index experienced a more significant peak-to-trough decline of 25% during the 2022 inflation shock and a 34% fall during the COVID-19 pandemic correction.
Furthermore, LLY stock has already absorbed some significant impact, having fallen over 20% from its 52-week high of over $970 to current levels below $750. In contrast, if you're more even handed, consider the Trefis High Quality strategy, has outperformed the market with more than 91% returns since inception - as evident in HQ performance metrics. Separately, see – Merck Stock's Ticking Keytruda Time Bomb
Winner In Obesity Drugs: If you generally believe the obesity is here to stay and with or without healthcare policy changes, Eli Lilly may not be a bad long-term bet, given its current position. Layer on the fact that Lilly, with its superior efficacy, is a leader in this obesity treatment race. The market for GLP-1 drugs is expected to grow to $150 billion by 2030, with Eli Lilly and Novo Nordisk currently dominating through their GLP-1 drugs that have collectively generated over $40 billion in sales last year. Worry about whether daily pills, weekly injections, or combination therapies will win the battle. The race may be too early to call, but Lilly is positioning itself across multiple fronts with both injectable Zepbound and promising oral GLP-1 formulations showing nearly 8% weight loss in trials.
What Could Go Wrong? Eli Lilly's earnings could disappoint, and its rapid growth might slow from 30% to around 20% in the coming years. This potential slowdown could be due to increased competition in the obesity treatment market, as more pharmaceutical companies are achieving success with their clinical trials. Notably, Boehringer Ingelheim, Amgen, Viking Therapeutics, and Roche are all developing promising therapies that could challenge Eli Lilly's market position.
Then there is the unexpected, unimagined. Definitely do not touch this if you can't stand more downside from here. Worse thing you could do is sell at that point. Instead talk to an adviser who's seen four bear markets in the last 30 years about Trefis HQ strategy plus other clever ways you can take advantage in the current market. Clue: much money is made in this market, if you don't lose your nerve. All said, if you're a long term investor and want to invest and forget for the next 3-5 years, Eli Lilly right now could be an interesting entry point.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Concert to raise money for cardiac screenings
A fundraising concert has been organised in memory of an eight-year-old boy who died from a cardiac arrest. Jasper Cook, from Birkenshaw, died in January 2022, three days after he fell ill with Covid-19. His parents, Kim and Ian Cook, said money raised from the event would be used to help fund cardiac screenings for young people. The event comes after Mrs Cook was nominated in the fundraiser category for this year's BBC Radio Leeds Make a Difference Awards. "My whole ethos behind what we've been doing in Jasper's name is, the more people I can reach, the more money I can raise, the more young hearts I can screen, the more people I can stop being in this terrible position," she said. "We have already now done three days and tested nearly 300 young people between the ages of 14 and 35." Since her son's death Mrs Cook has completed a number of fundraising challenges and events, including skydiving. The concert, taking place at St Paul's Church later, in Birkenshaw, will feature a choir from Birkenshaw primary school, as well as singers from St Paul's and the BBG Academy. It will also feature the first public performance of a song written by in memory of Jasper by his friend and her father, called A Song for Jasper. Mrs Cook said: "It's been a really difficult few years, but we are I think pulling through. "I think what we've been doing with the heart screening has really given us a little bit of focus. The BBC Make a Difference Awards are organised to thank and recognise people who want to improve the lives of people in the communities where they live, with the winners due to be announced at a ceremony in Bradford on 13 September Mrs Cook was nominated by a family friend who said: "It is truly remarkable that the family, despite their utter grief in dealing with the tragic loss of their young son, are honouring his memory by doing all that they can to prevent other families having to go through what they have suffered." Listen to highlights from West Yorkshire on BBC Sounds, catch up with the latest episode of Look North. Free heart checks in memory of eight-year-old boy Cardiac Risk in the Young
Yahoo
an hour ago
- Yahoo
Markets mixed as investors turn their attention to ECB rate decision
Markets are widely expecting the European Central Bank (ECB) to cut interest rates again at its monetary policy meeting later today. "At its most recent meeting in April, the ECB reduced its key interest rates by 25 basis points, bringing the deposit facility rate to 2.25%. Markets are now pricing in another cut in June, though expectations for further easing beyond that remain uncertain. A potential pause in July is gaining traction, as the ECB evaluates incoming economic data and inflation dynamics," market analysts at said. The latest decision will come as inflation in the euro area cooled more than expected in May, bolstering expectations that the ECB will announce another interest rate cut. Annual consumer price growth slowed to 1.9% in May, down from 2.2% in April, according to a flash estimate from Eurostat this week. The figure came in below economists' forecast of 2%, and marks the first time inflation has dipped below the ECB's 2% target since September 2024. The decline in headline inflation suggests that business uncertainty, partly driven by renewed global trade tensions and soft consumer demand, is weighing on pricing power across sectors. Core inflation, which strips out volatile food and energy prices, also showed signs of easing. It slowed to 2.4% in May, from 2.7% in April, falling below expectations of 2.5%. On a monthly basis, core prices rose by just 0.1%. Related Eurozone inflation falls below ECB 2% target in May: Rate cut in sight Meanwhile, Asian shares were mixed on Thursday, as Wall Street's big recent rally lost some momentum following a pair of potentially discouraging reports on the American economy. US futures edged lower and oil prices declined. Japan's benchmark Nikkei 225 shed 0.2% to 37,658.46, while Australia's S&P/ASX 200 declined nearly 0.1% to 8,535.10. In South Korea, the Kospi jumped 2.1% to 2,829.48 after the country's new president and leading liberal politician Lee Jae-myung began his term, vowing to restart talks with North Korea and beef up a trilateral partnership with the US and Japan. Hong Kong's Hang Seng gained 0.9% to 23,856.54, while the Shanghai Composite was little changed, inching down less than 0.1% to 3,374.30. On Wednesday, the S&P 500 finished the day virtually unchanged at 5,970.81 and remained 2.8% below its all-time high. The Dow Jones Industrial Average fell 0.2% to 42,427.74, and the tech-heavy Nasdaq composite added 0.3% to 19,460.49. The action was stronger in the bond market, where Treasury yields tumbled following weaker-than-expected economic updates. In other dealings early Thursday morning, benchmark US crude fell 8 cents to $62.77 a barrel. Brent crude, the international standard, edged up 1 cent to $64.87 a barrel. The US dollar rose to 142.87 Japanese yen from 142.78 yen. The euro cost $1.1413, little changed from $1.1418.
Yahoo
an hour ago
- Yahoo
Fears for safety of unborn babies after weight-loss jab alert
Pregnant women have been warned by the medical watchdog not to take weight-loss drugs as there is currently no guarantee there won't be any adverse affect on the baby. The Medicines and Healthcare products Regulatory Agency (MHRA) issued an alert over a lack of evidence for pregnancy safety for the jabs, which include Ozempic, Mounjaro, Wegovy, Saxenda and Victoza. The MHRA said the drugs – which are glucagon-like peptide-1 receptor agonists (GLP-1 or GLP-1 RAs) – must not be taken during pregnancy, while trying to get pregnant, or during breastfeeding. Anyone who gets pregnant while using the drugs should also stop taking the medicine, it added. It said: 'This is because there is not enough safety data to know whether taking the medicine could cause harm to the baby.' In some cases, women are also advised to continue using contraception for up to two months between stopping the medicine and trying to get pregnant. The MHRA said effective contraception includes the oral contraceptive pill, contraceptive implants, the coil and condoms. Those patients taking Mounjaro – which may reduce the effectiveness of oral contraceptives in people who are overweight – should also use condoms if they are on the Pill. The injections have been previously linked to a 'baby boom', with women reporting online that they have had surprise 'Ozempic babies' despite using contraception. To date, the MHRA has received more than 40 reports relating to pregnancy among women on the drugs. The MHRA said: 'This only applies to those taking Mounjaro and is especially important for the four weeks after starting Mounjaro and after any dose increase.' The advice on contraception is also contained in patient information leaflets that come with the medicines. MHRA data shared with by the PA news agency shows it has received 26 pregnancy-related reports for Mounjaro. It is not necessary for women to say whether the pregnancy was unintentional, though one report did say the pregnancy was such. There have been a further eight reports relating to pregnancy in people taking semaglutide (the ingredient in Ozempic and Wegovy). A further nine have been recorded for liraglutide (Victoza or Saxenda), of which one recorded the pregnancy was unintentional. The MHRA is also reminding people that weight-loss jabs should not be bought from unregulated sellers such as beauty salons or via social media, or taken without speaking to a health professional. Anyone who suspects they have had an adverse reaction or suspects their drug is not a genuine product, should report it to the MHRA Yellow Card scheme. Dr Alison Cave, MHRA chief safety officer, said: 'Skinny jabs are medicines licensed to treat specific medical conditions and should not be used as aesthetic or cosmetic treatments. 'They are not a quick fix to lose weight and have not been assessed to be safe when used in this way. 'Our guidance offers patients a 'one-stop shop' for our up-to-date advice on how to use these powerful medicines safely. 'This guidance should not be used as a substitute to reading the patient information leaflet or having a conversation with a healthcare professional as part of the prescribing process.' The latest guidance also reminds patients taking jabs of the symptoms to look out for in the event of acute pancreatitis which, although uncommon, can be serious. The main symptom is severe pain in the stomach that radiates to the back and does not go away, and people should seek immediate medical help. GLP-1 or GLP-1 RAs help people feel fuller by mimicking a natural hormone released after eating. Some, like Mounjaro, also act on a second hormone involved in appetite and blood sugar control. Jasmine Shah, medication safety officer at the National Pharmacy Association, said: 'Pharmacists urge women taking GLP-1 medicines to note this important new guidance from the MHRA published today and use effective contraception. 'Community pharmacies have been experiencing unprecedented levels of interest for weight-loss injections. 'It is therefore important that regulations and guidance keep pace with this demand and that patient safety is put at the heart of everything we do. 'Medicines are not like ordinary goods for sale; they must be handled with great care because they have the power to harm as well as to heal. 'We also reiterate warnings from the MHRA to avoid any potential fake weight loss injections sold on social media or via beauty salons, which could pose a serious risk to someone's health. 'We urge anyone who have concerns about this medication to speak to their pharmacist for advice.' Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.
